Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice

Alicia Lopez, Jose Rey Department of Pharmacy Practice, Nova Southeastern University, Fort Lauderdale, FL, USA Abstract: Schizophrenia is a complex, chronic psychiatric disorder associated with reduced quality of life and shortened life span. The majority of patients with schizophrenia will relaps...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lopez A, Rey J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Trinza Invega long-acting antipsychotic LAI Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/e91a8dbf01864803bf54112937a5245b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e91a8dbf01864803bf54112937a5245b
record_format	dspace
spelling	oai:doaj.org-article:e91a8dbf01864803bf54112937a5245b2021-12-02T05:42:10ZRole of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice1178-2021https://doaj.org/article/e91a8dbf01864803bf54112937a5245b2019-02-01T00:00:00Zhttps://www.dovepress.com/role-of-paliperidone-palmitate-3-monthly-in-the-management-of-schizoph-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Alicia Lopez, Jose Rey Department of Pharmacy Practice, Nova Southeastern University, Fort Lauderdale, FL, USA Abstract: Schizophrenia is a complex, chronic psychiatric disorder associated with reduced quality of life and shortened life span. The majority of patients with schizophrenia will relapse within 1 year following an acute episode. The ultimate goals of treatment are to improve functional capabilities, minimize residual symptoms during periods of remission, and decrease relapse frequency and duration, as each relapse brings with it the possibility of a worsening prognosis. Maintaining therapeutic continuity is essential for long-term, positive patient outcomes in schizophrenia. Medication nonadherence and symptomatic relapses magnify the disease burden associated with this disorder. Medication adherence in chronic disease states generally improves with a decrease in dosing frequency. Long-acting injectable (LAI) antipsychotics were developed to improve patient outcomes secondarily to improving medication adherence. Paliperidone palmitate 3-monthly injection (PP3M) is the only LAI available with a quarterly dosing interval. PP3M has been US Food and Drug Administration-approved for use in the long-term maintenance treatment of schizophrenia in patients already controlled on once-monthly PP LAI (paliperidone palmitate once-monthly injection [PP1M]) for a minimum of 4 months. As current evidence supports the efficacy and tolerability of PP3M compared to PP1M and placebo, PP3M appears to be a viable treatment option for patients previously maintained on PP1M. However, to truly establish the place of PP3M in therapy relative to other oral antipsychotics and LAIs, more research is needed. This narrative review aims briefly to describe the pharmacotherapeutic characteristics of PP3M and summarize current literature pertaining to the use of PP3M in the management of schizophrenia. Keywords: Trinza, Invega, long-acting, antipsychotic, LAILopez ARey JDove Medical PressarticleTrinzaInvegalong-actingantipsychoticLAINeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 449-456 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Trinza Invega long-acting antipsychotic LAI Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Trinza Invega long-acting antipsychotic LAI Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Lopez A Rey J Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
description	Alicia Lopez, Jose Rey Department of Pharmacy Practice, Nova Southeastern University, Fort Lauderdale, FL, USA Abstract: Schizophrenia is a complex, chronic psychiatric disorder associated with reduced quality of life and shortened life span. The majority of patients with schizophrenia will relapse within 1 year following an acute episode. The ultimate goals of treatment are to improve functional capabilities, minimize residual symptoms during periods of remission, and decrease relapse frequency and duration, as each relapse brings with it the possibility of a worsening prognosis. Maintaining therapeutic continuity is essential for long-term, positive patient outcomes in schizophrenia. Medication nonadherence and symptomatic relapses magnify the disease burden associated with this disorder. Medication adherence in chronic disease states generally improves with a decrease in dosing frequency. Long-acting injectable (LAI) antipsychotics were developed to improve patient outcomes secondarily to improving medication adherence. Paliperidone palmitate 3-monthly injection (PP3M) is the only LAI available with a quarterly dosing interval. PP3M has been US Food and Drug Administration-approved for use in the long-term maintenance treatment of schizophrenia in patients already controlled on once-monthly PP LAI (paliperidone palmitate once-monthly injection [PP1M]) for a minimum of 4 months. As current evidence supports the efficacy and tolerability of PP3M compared to PP1M and placebo, PP3M appears to be a viable treatment option for patients previously maintained on PP1M. However, to truly establish the place of PP3M in therapy relative to other oral antipsychotics and LAIs, more research is needed. This narrative review aims briefly to describe the pharmacotherapeutic characteristics of PP3M and summarize current literature pertaining to the use of PP3M in the management of schizophrenia. Keywords: Trinza, Invega, long-acting, antipsychotic, LAI
format	article
author	Lopez A Rey J
author_facet	Lopez A Rey J
author_sort	Lopez A
title	Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
title_short	Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
title_full	Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
title_fullStr	Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
title_full_unstemmed	Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
title_sort	role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/e91a8dbf01864803bf54112937a5245b
work_keys_str_mv	AT lopeza roleofpaliperidonepalmitate3monthlyinthemanagementofschizophreniainsightsfromclinicalpractice AT reyj roleofpaliperidonepalmitate3monthlyinthemanagementofschizophreniainsightsfromclinicalpractice
_version_	1718400266550640640

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice

Ejemplares similares